Wanu Seo

Wanu Seo

Auto-generated profile, based on publicly available information

Wanu Seo

Department of Education and Training, Asan Medical Center, Seoul, Korea

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Korean Medical Science
Verified
Journal Article
Open access
MJMin-Woo Jo
Min-Woo Jo
WSWanu Seo
Wanu Seo
SLSo Yun Lim
So Yun Lim
MOMinsu Ock
Minsu Ock
Jo MW, et al. J Korean Med Sci. 2019 Mar;34(Suppl 1):e88. https://doi.org/10.3346/jkms.2019.34.e88

1 October 2024 in Korean Journal of Anesthesiology
Verified
Journal Article
Open access
PDF file
JKJi-Hyeon Kim
Ji-Hyeon Kim
JNJae-Sik Nam
Jae-Sik Nam
WSWan-Woo Seo
Wan-Woo Seo
KJKyoungwoon Joung
Kyoungwoon Joung
JCJi-Hyun Chin
Ji-Hyun Chin
ICIn-Cheol Choi
In-Cheol Choi
Background: Minimalist transcatheter aortic valve replacement (TAVR) under monitored anesthesia care (MAC) emphasizes early recovery. Remimazolam is a novel benzodiazepine with a short recovery time. This study hypothesized that remimazolam is non-inferior to dexmedetomidine in terms of recovery after TAVR.Methods: In this retrospective observational study, remimazolam was compared to dexmedetomidine in patients who underwent TAVR under MAC at a tertiary academic hospital between July 2020 and July 2022. The primary outcome was timely recovery after TAVR, defined as discharge from the intensive care unit within the first day following the procedure. Propensity score matching was used to compare timely recovery between remimazolam and dexmedetomidine, applying a non-inferiority margin of -10%.Results: The study included 464 patients, of whom 218 received remimazolam and 246 received dexmedetomidine. After propensity score matching, 164 patients in each group were included in the analysis. Regarding timely recovery after TAVR, remimazolam was non-inferior to dexmedetomidine (152 of 164 [92.7%] in the remimazolam group versus 153 of 164 [93.3%] in the dexmedetomidine group, risk difference [95% CI]: −0.6% [−6.7%, 5.5%]). The use of remimazolam was associated with fewer postoperative vasopressors/inotropes (21 of 164 [12.8%] vs. 39 of 164 [23.8%]) and temporary pacemakers (TPMs) (76 of 164 [46.3%] vs. 108 of 164 [65.9%]) compared to dexmedetomidine.Conclusions: In patients undergoing TAVR under MAC, remimazolam was non-inferior to dexmedetomidine in terms of timely recovery. Remimazolam may be associated with better postoperative recovery profiles, including a lesser need for vasopressors/inotropes and TPMs.

1 January 2018 in Journal of Korean Medical Science
Verified
Journal Article
Open access
MJMin-Woo Jo
Min-Woo Jo
WSWanu Seo
Wanu Seo
SLSo Yun Lim
So Yun Lim
MOMinsu Ock
Minsu Ock
Jo MW, et al. J Korean Med Sci. 2018 Oct;33(53):e301. https://doi.org/10.3346/jkms.2018.33.e301